

Product Data Sheet

Product Name: Colestilan

Cat. No.: GC74877

Chemical Properties

Cas. No. 95522-45-5

Formula $(C_4H_6N_2.C_3H_5ClO)_x$

M.Wt N/A


Solubility

Storage -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research^{[1][2]}.

Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract^[2]. Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH 7.2 in vitro^[2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats^[3]. Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks^[1].

References:

- [1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. *Nephrol Dial Transplant*. 2010 Feb;25(2):574-81.
- [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. *Nephrol Dial Transplant*. 2005 Feb;20(2):424-30.
- [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA